2096328-94-6

2096328-94-6 structure

Name: Pozelimab
Chemical Name: Pozelimab
CAS Number: 2096328-94-6
Molecular Formula:
Molecular Weight:
Catalog: Signaling Pathways Immunology/Inflammation Complement System
Create Date: 2023-03-11 13:24:10
Modify Date: 2024-04-07 00:46:59
Pozelimab (REGN3918) is a fully human IgG4 anti-C5 monoclonal antibody. Pozelimab binds to C5 and C5 variants with high affinity and blocks complement-mediated hemolysis. Pozelimab can be used for the research of complement-mediated diseases[1].

Name	Pozelimab

Description	Pozelimab (REGN3918) is a fully human IgG4 anti-C5 monoclonal antibody. Pozelimab binds to C5 and C5 variants with high affinity and blocks complement-mediated hemolysis. Pozelimab can be used for the research of complement-mediated diseases[1].
Related Catalog	Signaling Pathways >> Immunology/Inflammation >> Complement System Research Areas >> Metabolic Disease
In Vitro	Pozelimab 与人 C5 和食蟹猴 C5 结合的 Kd 值分别为 262 pM 和 8.55 nM 在 37˚C，pH7.4 的条件下[1]。 Pozelimab 阻断代表性通路 (CP) 介导的人和食蟹猴血清溶血，IC50 值分别为 2.8 和 20 nM 在 37˚C，pH7.4 的条件下[1]。 Pozelimab 阻断替代途径 (AP) 介导的正常人和食蟹猴血清溶血，IC50 值分别为 26 和 8.9 nM 在 37˚C，pH7.4 的条件下[1]。 Pozelimab 与人 C5，食蟹猴 C5，人 R885C C5 和人 C5b,6 结合的 Kd 值分别为 0.189，2.73，0.422，0.465 和 0.137 nM 在 25˚C，pH7.4 时[1]。
In Vivo	Pozelimab (15 mg/kg；皮下注射，1 次) 在雄性和雌性 C5hu/hu 小鼠中，具有较长的药代动力学参数，半衰期约为 13 天[1]。 Animal Model: Cynomolgus monkey[1] Dosage: 15 mg/kg Administration: Intravenous injection; 15 mg/kg, once Result: Showed a a greater exposure to monkeys compared with H4H12161P and H4H12170P.
References	[1]. Latuszek A, et al. Inhibition of complement pathway activation with Pozelimab, a fully human antibody to complement component C5. PLoS One. 2020 May 8;15(5):e0231892.

No Any Chemical & Physical Properties